Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Teva Presents New Phase 3 Efficacy, Safety And Tolerability Data From Solaris Trial Evaluating Tev ‘749 Olanzapine As A Once Monthly Subcutaneous Long Acting Injectable For Adult Patients Diagnosed With Schizophrenia is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from ...
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients ... Read More
Teva Presents Latest Schizophrenia Treatment Research, Including Phase ...
Teva’s presentation of findings from six schizophrenia studies at Psych Congress 2024 highlights its commitment to finding new innovations in neuroscience Data show TEV-'749 drug delivery ... Read More
Medincell’s Partner Teva Presented New Efficacy, Safety, and ...
Teva presented at ECNP 2024* new positive efficacy, safety, and tolerability results for Phase 3 SOLARIS trial evaluating Olanzapine LAI (TV-‘749 / mdc-TJK) in adult patients diagnosed with ... Read More
Teva and Medincell Announce Positive Phase 3 Efficacy Results from ...
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia ... Read More
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from ...
As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia, including TEV-‘749Currently, there is no long ... Read More
Teva Presents Latest Schizophrenia Treatment Research, Including Phase ...
SOLARIS is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of olanzapine extended-release ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus